Preoperative imaging evaluation of the absolute indication criteria for endoscopic submucosal dissection in early gastric cancer patients

Hong-Peng Shi 1, Wei Wu 1, Ben-Yan Zhang 1, Maneesh-Kumarsing Beeharry 1, Tie-Nan Feng 1, Zheng-Gang Zhu 1, Fei Yuan 1, Zhenglun Zhu 1

1Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
2School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Abstract

Introduction: Gastric cancer (GC) is a common malignant tumor with a high mortality rate. Aim: To determine the accuracy of preoperative imaging information obtained from the combined use of general gastroscopy (GS), endoscopic ultrasonography (EUS), and multi-detector computed tomography (MDCT) regarding absolute indication of endoscopic submucosal dissection (ESD) in early gastric cancer (EGC).

Material and methods: The relationship between clinical features of 794 EGC patients and lymph node metastasis (LNM) was analyzed. Multivariate logistic regression analysis was used to investigate the risk factors for LNM. Additionally, the accuracy of diagnosis of imaging techniques for ESD indications was determined by receiver operating characteristic (ROC) analysis.

Results: Data showed that tumor size > 2 cm (p = 0.0071), T1b stage (p < 0.0001), undifferentiated histology (p < 0.0001), and vascular invasion (p = 0.0007) were independent risk factors for LNM in patients with EGC. Indications for ESD have a specificity of 100% for the diagnosis of patients with LNM. Additionally, the diagnostic efficacy of the use of GS, EUS, and MDCT in identifying node positive status, T1a disease, tumor size ≤ 2 cm, and ulceration was found to be moderate with area under the curve (AUC) of receiver operating characteristic curve (ROC) of 0.71, 0.64, 0.72, and 0.68, respectively. Furthermore, the use of imaging techniques for overall indication criteria for ESD had a moderate utility value with an AUC of 0.71.

Conclusions: Our data suggested that, based on the combined use of GS, EUS, and MDCT, a high specificity of patient selection for ESD treatment can be achieved.

Key words: early gastric cancer, endoscopic submucosal dissection, absolute indication.

Introduction

The incidence of gastric cancer (GC) has been declining steadily over the past 70 years [1]; however, GC remains the fourth most common malignancy and the third leading cause of cancer-related mortality worldwide [2, 3], with a million cases diagnosed annually. GC is often either asymptomatic or causes non-specific symptoms only. By the time symptoms appear, the cancer has often reached an advanced stage and may have metastasized. Despite enormous progress in medical technology, the outcome of patients with GC remains poor [4]. Therefore, early detection and treatment of GC is necessary to im-
prove the prognosis of GC. Early gastric cancer (EGC), as defined by the Japanese Society of Gastroenterological Endoscopy in 1962, is invasive GC that invades no more deeply than the submucosa, irrespective of lymph node metastasis (LNM), and it denotes early lesion features of the disease. Today, the superior prognosis of EGC has led to the development of better screening protocols in high risk populations [5–7] and better surveillance guidelines for gastric premalignant lesions.

Recently, endoscopic submucosal dissection (ESD) has revolutionized the treatment of EGC, with the rates of post-therapeutic morbidities and mortalities, hospital stays and financial burden lower than with surgery [8–11]. Moreover, ESD should be applicable to GC patients when following criteria including highly differentiated pathology, clinically node negative status, lesions involving the mucosa, non-ulcerated lesions, and lesion size of less than or equal to 2 cm. However, these criteria are established after postoperative pathology analysis of a large sample of EGC patients. Hence, it is urgent to determine whether the absolute indications of ESD can be identified by non-invasive techniques such as imaging.

Aim

In the present study, we analyzed the postoperative pathological features of patients with EGC who received surgical treatment in Ruijin Hospital from 2012 to 2016, and verified the diagnostic value of ESD indications in LNM. Meanwhile, to determine whether preoperative imaging methods can accurately predict the indications of ESD, ESD indications measured by ES, EUS, and MDCT were compared with the results of postoperative pathological diagnosis.

Material and methods

The study was approved by the institutional Ethics Committee of Ruijin Hospital and followed the principles of the Declaration of Helsinki. Written informed consent was obtained from each participant.

Segment I

Patients

To investigate whether absolute indication criteria (such as tumor size, depth of invasion, ulceration, and differentiation) for ESD are enough to preoperatively determine the lymph node status of EGC patients, a total of 794 patients with postoperative pathology-proven EGC in our organization between 2012 and 2016 were enrolled in this study. Moreover, clinicopathologic characteristics of all patients, such as age, sex, tumor size, differentiation grade, T stage, the presence or absence of ulceration, the presence or absence of lymphovascular/neural involvement, and HER-2 expression were obtained and are summarized in Table I.

Inclusion and exclusion criteria

The patients were selected based on the following inclusion criteria: (1) no age or sex bias, (2) patients with GC who underwent standard gastrectomy with D2 lymphadenectomy in Ruijin Hospital between 2012 and 2016, (3) postoperative pathology confirmed EGC (pT1 disease). Exclusion criteria were: (1) the presence of synchronous lesions where one or more were T2 or higher, (2) gastrectomy performed after ESD where no tumor residue was found, (3) patients with biopsy proven GC before surgery but no tumor cells identified in postoperative pathology.

Procedure

Based on the data collected from patients, the relationship between the clinicopathological features of EGC and lymph node metastasis was investigated. Briefly, the probability of LNM was studied by age, gender, tumor size, differentiation grade, depth of tumor invasion, presence or absence of ulceration, lymphatic/vascular/nerve invasion, and HER-2 expression.

Segment II

Patients

To determine whether the combined use of GS, EUS, and MDCT could help identify EGC patients meeting the absolute indications for ESD, 86 patients with EGC confirmed by pathological biopsy and suspected by gastroscopy in our organization between January and December, 2017, were included in the study. All participants were preoperatively staged using GS, EUS and MDCT. The absolute indications for ESD for all patients, including tumor size, depth of invasion, ulceration, and differentiation were collected.
Table I. The association between LNM and other clinicopathological factors in EGC (N = 794)

| Variables                  | LNM | P-value | Rates of metastasis in different subgroups |
|----------------------------|-----|---------|-------------------------------------------|
|                            | Yes (n = 138) | No (n = 656) |                                           |
| Age [years]:               |     |         |                                           |
| ≤ 44                       | 19  | 63      | 19/82 (23.1%)                             |
| 45–59                      | 55  | 223     | 51/203 (25.1%)                            |
| 60–74                      | 50  | 302     | 37/202 (18.3%)                            |
| ≥ 75                       | 14  | 68      | 7/35 (20%)                                |
| Sex:                       |     |         |                                           |
| Male                       | 86  | 432     | 86/518 (22.1%)                            |
| Female                     | 53  | 224     | 53/277 (19.1%)                            |
| Ulceration:                |     |         |                                           |
| Yes                        | 68  | 228     | 68/296 (17.2%)                            |
| No                         | 70  | 428     | 70/498 (14.1%)                            |
| Lesion size [cm]:         |     |         |                                           |
| ≤ 2                        | 75  | 450     | 75/525 (14.3%)                            |
| > 2                        | 63  | 206     | 63/269 (23.4%)                            |
| Invasion depth:            |     | < 0.0001|                                           |
| Mucosa                     | 29  | 346     | 29/375 (8.73%)                            |
| Submucosa                  | 109 | 310     | 109/419 (26.1%)                           |
| Tumor location:            |     |         |                                           |
| Upper 1/3                  | 11  | 56      | 11/67 (16.4%)                             |
| Middle 1/3                 | 45  | 245     | 45/290 (15.5%)                            |
| Lower 1/3                  | 82  | 355     | 82/437 (18.8%)                            |
| Differentiation:           |     | < 0.0001|                                           |
| Poor                       | 114 | 403     | 114/517 (22.1%)                           |
| Non-poor                   | 24  | 253     | 24/277 (8.7%)                             |
| Lymphatic invasion:        |     | 0.0038  |                                           |
| Yes                        | 4   | 1       | 4/5 (80%)                                 |
| No                         | 134 | 655     | 134/789 (17.0%)                           |
| Vascular invasion:         |     | < 0.0001|                                           |
| Yes                        | 34  | 45      | 34/79 (43.0%)                             |
| No                         | 104 | 611     | 104/715 (14.5%)                           |
| Neural invasion:           |     | 0.010   |                                           |
| Yes                        | 5   | 4       | 5/9 (55.6%)                               |
| No                         | 133 | 652     | 133/785 (16.9%)                           |
| Her-2 expression:          |     | 0.003   |                                           |
| Positive                   | 10  | 111     | 10/121 (8.3%)                             |
| Negative                   | 128 | 545     | 128/673 (19.0%)                           |
Inclusion criteria

Inclusion criteria were: (1) no age or sex bias, (2) patients with biopsy proven GC, suspected to be EGC in initial gastroscopy, (3) diagnostic gastroscopy performed at the digestive endoscopy center of Ruijin Hospital from January to December 2017, (4) patients who have undergone EUS and MDCT for preoperative staging after admission to the department of Gastrointestinal Surgery, ward III, (5) patients who had undergone standard gastrectomy with D2 lymphadenectomy as the definitive therapeutic intervention.

Procedure

After collection of relevant data for the 86 selected patients, preoperative imaging information acquired from MDCT and EUS was separately compared to subsequent postoperative pathology. The procedure was as follows: (1) diagnosis of tumor depth, i.e. the capacity of EUS and MDCT to differentiate T1a and T1b disease was compared to postoperative pathology, (2) diagnosis of node negative status, i.e. the capacity of EUS and MDCT to differentiate clinically node positive (cN+) and clinically node negative (cN-) status was compared to postoperative pathology, (3) identification of the presence or absence of ulcerative findings in gastroscopy was compared to that of postoperative pathology, (4) endoscopic measurements of the lesion size were compared to that of postoperative pathology, (5) accuracy of preoperative imaging in determining the absolute indication criteria for endoscopic treatment was investigated by comparing combined preoperative information with postoperative pathology.

Statistical analysis

All data processing was done using SPSS 21.0 software, and measurement data were expressed as mean ± SD. The χ² test and Fisher’s exact probability test were used to compare the differences in rates of LNM in different subgroups. P < 0.05 indicates statistical significance. Multivariate logistic regression analysis was performed to identify independent risk factors for LNM in EGC. Receiver operating characteristic (ROC) was used to analyze the accuracy of the combined use of GS, EUS and MDCT in predicting absolute indication criteria for ESD.

Results

Segment I

Relationship of LNM with other clinicopathological status in patients with EGC

As shown in Table II, 794 patients were divided into two groups: the LNM+ group and the LNM− group. The results showed that LNM was significantly associated with ulceration (p = 0.0019), lesion size (p = 0.0018), invasive depth (p < 0.0001), differentiation (p < 0.0001), lymphatic invasion (p = 0.0038), vascular invasion (p < 0.0001), neural invasion (p = 0.01) and HER-2 expression (p = 0.003). However, no significant differences were found between LNM and other clinical parameters, such as age, sex, and tumor location (all, p > 0.05).

Moreover, multivariate logistic regression analysis of independent risk factors for LNM revealed that tumor diameter (p = 0.0071), pT (p < 0.0001), differentiation (p = 0.0001), and vessel invasion (p = 0.0007) were independent risk factors for LNM in patients with EGC.

Diagnostic value of the absolute indications of ESD for LNM

Next, we assessed the potential value of absolute indications of ESD for clinical diagnosis of LNM in 794 patients with EGC. The results showed that ESD indications could effectively distinguish EGC patients with LNM from those with no LNM with an AUC of 0.69 (p < 0.05) (Figure 1; Table III).

Segment II

General clinicopathological features of the subjects

As illustrated in Table IV, there were 54 male and 32 female patients with ages ranging from 33 to 83 years old. During preoperative workup, 44 patients were identified as having nodal involvement (EUS and CT combined), 38 patients as having a tumor size of 2 cm or smaller, 20 patients were diagnosed with mucous disease (T1a, by EUS), and 20 patients had ulcerative lesions on gastroscopy. Tumor location was at the upper third, middle third and lower third of the stomach for 8, 36, and 42 patients,
respective. During examination of postoperative pathology specimens, 24 patients had lymph node metastasis, 52 patients had a lesion sized 2 cm or smaller, 44 patients had T1a disease and 30 patients had lesions with ulcerative findings.

Diagnostic utility values of EUS, MDCT, or EUS + MDCT for tumor depth

With postoperative pathology as the standard of reference, the diagnostic accuracy values of EUS, MDCT and EUS + MDCT in clinical diagnosis of tumor depth at T1a given by AUC of ROC were 0.63 (sensitivity: 36.36%; specificity: 90.48%), 0.79 (sensitivity: 63.64%; specificity: 95.24%) and 0.64 (sensitivity: 27.27%; specificity: 100%) (Figure 2 A), respectively.

Diagnostic utility values of EUS, MDCT, or EUS + MDCT for LNM

The AUC values of EUS, MDCT and EUS + MDCT in clinical diagnosis of LNM at N stage were 0.73 (sensitivity: 57.14%; specificity: 86.20%), 0.51 (sensitivity: 25%; specificity: 77.42%) and 0.71 (sensitivity: 75%; specificity: 67.74%) (Figure 2 B), respectively.

Diagnostic utility values of GS for tumor size

Additionally, with the GS, the AUC values of the ulcerative findings and tumor size were 0.68 (sensitivity: 57.14%; specificity: 86.20%), 0.51 (sensitivity: 25%; specificity: 77.42%) and 0.71 (sensitivity: 75%; specificity: 67.74%) (Figure 2 B), respectively.

| Parameter | LN metastasis | AUC | Rates of LNM in different subgroups | Sensitivity | Specificity |
|-----------|---------------|-----|-------------------------------------|-------------|-------------|
| ESD absolute indications | No (n = 656) | Yes (n = 138) | 0.69 | 37.84% | 100% |
| Compliance | 84 | 0 | 0/84 (0%) | | |
| Non-compliance | 572 | 138 | 138/710 (19.4%) | | |
and 0.72 (sensitivity: 61.54%; specificity: 82.35%), respectively. More importantly, the correlation coefficient of the tumor size between endoscopic measurements (tumor diameter: 2.81 ±0.23) and postoperative specimen measurements (2.71 ±0.22) was 0.98, indicating that gastroscopy could accurately reflect the pathological size of the tumor.

**Combined diagnostic value of imaging for absolute indication criteria**

Based on the postoperative pathology results, the diagnostic accuracy of using all imaging techniques for the preoperative assessment of ESD indications was investigated. As illustrated in Figure 3 B, the AUC was 0.71 with a sensitivity of 42.86% and a specificity of 100%. This suggests that the combined use of GS, EUS and MDCT has a high specificity for selecting suitable candidates for ESD treatment.

**Discussion**

During the past few years, an increasing number of studies have been able to predict trends of LNM in EGC on the basis of endoscopic findings and clinicopathological features of primary lesions. For instance, Kwee and Kwee [10] identified location of the tumor in the middle stomach, larger tumor size, depressed tumor type, ulceration, diffuse histologic type, and lymphatic tumor invasion as risk factors for LN metastasis in EGC. Kurihara et al. [12] reported

---

**Table IV. Clinicopathological characteristics of preoperative imaging and post-operative pathology**

| Parameter                  | N+ | N– | ≤ 2 cm | > 2 cm | T1a | T1a+ | UL(+) | UL(–) |
|----------------------------|----|----|--------|--------|-----|------|-------|-------|
| Preoperative imaging:      |    |    |        |        |     |      |       |       |
| Age [years]:               |    |    |        |        |     |      |       |       |
| ≥ 60                       | 24 | 26 | 22     | 28     | 12  | 38   | 10    | 26    |
| < 60                       | 20 | 16 | 16     | 20     | 8   | 28   | 10    | 40    |
| Sex:                       |    |    |        |        |     |      |       |       |
| Male                       | 30 | 24 | 26     | 28     | 12  | 42   | 8     | 42    |
| Female                     | 14 | 18 | 12     | 20     | 8   | 24   | 12    | 20    |
| Tumor location:            |    |    |        |        |     |      |       |       |
| U 1/3                      | 4  | 4  | 6      | 2      | 0   | 8    | 2     | 6     |
| M 1/3                      | 18 | 18 | 12     | 24     | 8   | 28   | 14    | 22    |
| L 1/3                      | 22 | 20 | 20     | 22     | 12  | 30   | 4     | 38    |
| Post-operative pathology:  |    |    |        |        |     |      |       |       |
| Age [years]:               |    |    |        |        |     |      |       |       |
| ≥ 60                       | 14 | 36 | 34     | 16     | 22  | 28   | 14    | 34    |
| < 60                       | 10 | 26 | 18     | 18     | 22  | 14   | 16    | 22    |
| Sex:                       |    |    |        |        |     |      |       |       |
| Male                       | 14 | 40 | 30     | 24     | 30  | 24   | 18    | 36    |
| Female                     | 10 | 22 | 22     | 10     | 14  | 18   | 12    | 20    |
| Tumor location:            |    |    |        |        |     |      |       |       |
| U 1/3                      | 4  | 4  | 4      | 4      | 4   | 4    | 4     | 4     |
| M 1/3                      | 8  | 28 | 24     | 12     | 24  | 12   | 14    | 22    |
| L 1/3                      | 12 | 30 | 24     | 18     | 16  | 26   | 12    | 30    |
Preoperative imaging evaluation of the absolute indication criteria for endoscopic submucosal dissection in early gastric cancer patients

**Figure 2.** ROC of EUS, MDCT and EUS + MDCT to predict tumor depth (A) and lymph node involvement (B) in EGC patients.

**Figure 3.** ROC of gastroscopy to predict tumor ulceration (A) and ESD absolute indication evaluated by GS, EUS and MDCT to predict EGC in patients (B).
that tumor diameter, lymphatic invasion, and depth of invasion were associated with LNM. Moreover, a previous study reported that the rates of metastasis in patients fulfilling absolute and expanded criteria for ESD were found to be low, at 0.3% and 0.4%, respectively [13]. In accordance with previous studies, our data revealed that clinical features, including tumor size above 2 cm, poorly differentiated pathology, tumor depth invasion below the mucosa, and vascular invasion are associated with higher risks of locoregional lymph node involvement. Moreover, none of the 84 cases fulfilling the absolute criteria of ESD were found to have LNM and ESD indications could effectively distinguish EGC patients with LNM from those with no LNM. Taken together, these data indicate that absolute criteria of ESD for EGC are safe and effective for screening patients with LNM.

Given that currently the rates of post-therapeutic morbidity and mortality, hospital stays, and financial burden are lower than for surgery [14–16], the indications of ESD have been accepted by an increasing number of surgeons [17]. However, due to the inaccuracy of preoperative evaluation, patients with EGC are usually treated with standard surgery again after ESD, which will increase the risk of surgery for patients [18]. Hence, an accurate preoperative identification of absolute indication criteria for ESD is of great importance. With the rapid development of endoscopic technology and accumulation of ESD data, a new guideline of ESD indication based on endoscopic imaging will lead to a more accurate patient selection for ESD [19]. As a crucial factor to predict LNM in patients with EGC, tumor size measured by GS has been found to be lower than that of postoperative pathological measurements [20]; however, the difference in tumor size between preoperative and postoperative measurements was small, at less than 0.4 cm in approximately 80% of patients. In the present study, our data suggest that GS could distinguish EGC patients with a tumor diameter ≤ 2 cm from those with a tumor diameter > 2 cm with an AUC of 0.72. Moreover, a strong correlation was observed between endoscopic measurements of tumor size and measurements of the postoperative specimen.

The degree of GC ulcer mainly depends on the diameter and depth of the lesion, but endoscopic diagnosis of GC ulcer formation is difficult [19, 21]. Usually, endoscopic examination leads to a high estimation of ulceration, which leads to patients fulfilling the absolute criteria of ESD to miss their chance of treatment. In the present study, endoscopic diagnosis of ulcerative lesions was shown to have a sensitivity and specificity of 89.29% and 46.67%, respectively, with an AUC of 0.68. EUS has been regarded as one of the most valuable methods for detection of the infiltration depth of EGC, with an accuracy of 60–90% for T stage [22–24]. Moreover, MDCT in the detection of T stage and N stage of GC was 77–89% and 69–92%, but its accuracy in the diagnosis of EGC was low [25]. In our study, the results showed that the accuracy of MDCT diagnosis for EGC infiltration depth at T1a stage was superior to that of EUS or EUS + MDCT. On the other hand, in comparison to MDCT or EUS + MDCT, the accuracy of EUS for measuring EGC lymph node involvement at N stage was higher. Actually, both Hasegawa and Aoyagi et al. [26, 27] showed that highly differentiated non-ulcerative cases could present with LNM and therefore preoperative diagnosis of lymph node involvement becomes particularly important. Finally, preoperative assessments of ESD indications from all imaging information were compared with postoperative pathology, and the results of sensitivity and specificity were 42.86% and 100%, respectively.

Conclusions

Our data showed that the absolute indications of EGC were safe with no risks of LNM for patients. Moreover, based on the combined use of GS, EUS and MDCT, a high specificity of patient selection for ESD treatment can be achieved. Nevertheless, our study has several limitations. Firstly, the sample size was small, as only 86 patients fulfilled the inclusion criteria for selection with imaging information. Secondly, imaging information was incomplete. Hence, further comprehensive and large-scale studies are still needed to confirm our findings.

Conflict of interest

The authors declare no conflict of interest.

References

1. Parkin DM. Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594–606.
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (37 Suppl 8): 4–66.
3. Parkin DM. International variation. Oncogene 2004; 23: 6329–40.
Preoperative imaging evaluation of the absolute indication criteria for endoscopic submucosal dissection in early gastric cancer patients

4. Ang TL, Fock KM. Clinical epidemiology of gastric cancer. Singapore Med J 2014; 55: 621-8.
5. Mori Y, Kudo SE, Mohmed HEN, et al. Artificial intelligence and upper gastrointestinal endoscopy: current status and future perspective. Dig Endosc 2019; 31: 378-88.
6. Liu MM, Wen L, Liu YJ, et al. Application of data mining methods to improve screening for the risk of early gastric cancer. BMC Med Inform Decis Mak 2018; 18 (Suppl 5): 121.
7. Kula ZK, Zegarski W, Jóźwicki W. Diagnosis and treatment of early gastric cancer: experience of one center. Gastroenterology Rev 2018; 13: 200-5.
8. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 1981; 11: 127-39.
9. Wang AY, Draganov PV. Training in endoscopic submucosal dissection from a Western perspective. Tech Gastrointest Endosc 2017; 19: 159-69.
10. Kwee RM, Kwee TC. Predicting lymph node status in early gastric cancer. Gastric Cancer 2008; 11: 134-48.
11. He D, Cao X, Luo T, et al. Endoscopic submucosal dissection for colorectal laterally spreading tumors with the Dual knife only. Videosurgery Miniov 2019; 14: 495-500.
12. Kurihara N, Kubota T, Otani Y, et al. Lymph node metastasis of early gastric cancer with submucosal invasion. Br J Surg 1998; 85: 835-9.
13. Choi K, Bae JM, Kim SM, et al. The risk of lymph node metastases in 3951 surgically resected mucosal gastric cancers: implications for endoscopic resection. Gastrointest Endosc 2016; 83: 896-901.
14. Zhao S, Zhang X, Wang J, et al. Endoscopic resection versus surgery for early gastric cancer and precancerous lesions: a meta-analysis. Springerplus 2016; 5: 678.
15. Kondo A, de Moura EG, Bernardo WM, et al. Endoscopy vs surgery in the treatment of early gastric cancer: systematic review. World J Gastroenterol 2015; 21: 13177-87.
16. Guo TJ, Qin JY, Zhu LL, et al. Feasible endoscopic therapy for early gastric cancer. World J Gastroenterol 2015; 21: 13325-31.
17. Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3: 219-25.
18. Shin N, Jeon TY, Kim GH, Park DY. Unveiling lymph node metastasis in early gastric cancer. World J Gastroenterol 2014; 20: 5389-95.
19. Park SM, Kim BW, Kim JS, et al. Can endoscopic ulcerations in early gastric cancer be clearly defined before endoscopic resection? A survey among endoscopists. Clin Endosc 2017; 50: 473-8.
20. Choi J, Kim SG, Im JP, et al. Endoscopic estimation of tumor size in early gastric cancer. Dig Dis Sci 2013; 58: 2329-36.
21. Lee HJ. Identification of ulceration in early gastric cancer before resection is not easy: need for a new guideline for endoscopic submucosal dissection indication based on endoscopic image. Clin Endosc 2017; 50: 410-1.
22. Papanikolaou IS, Triantafyllou M, Triantafyllou K, Rosch T. EUS in the management of gastric cancer. 2011; 24: 9-15.
23. Razavi SM, Khodadost M, Sohrabi M, et al. Accuracy of endoscopic ultrasonography for determination of tumor invasion depth in gastric cancer. Asian Pac J Cancer Prev 2015; 16: 3141-5.
24. Okada K, Fujisaki J, Kasuga A, et al. Endoscopic ultrasonography is valuable for identifying early gastric cancers meeting expanded-indication criteria for endoscopic submucosal dissection. Surg Endosc 2011; 25: 841-8.
25. Hallinan JT, Venkatesh SK. Gastric carcinoma: imaging diagnosis, staging and assessment of treatment response. Cancer imaging 2013; 13: 212-7.
26. Hasegawa F, Takata O, Tokai K, et al. Lymphatic invasion in small differentiated-type mucosal gastric cancer. Clin J Gastroenterol 2012; 5: 234-8.
27. Aoyagi K, Koufuji K, Yano S, et al. A case of small mucosal gastric carcinoma with lymph node metastasis: a case report. Kurume Med J 2003; 50: 49-51.

Received: 23.12.2019, accepted: 24.02.2020.